TA
MCID: TKY002
MIFTS: 61

Takayasu Arteritis (TA)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Fetal diseases, Nephrological diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Takayasu Arteritis

MalaCards integrated aliases for Takayasu Arteritis:

Name: Takayasu Arteritis 57 12 73 20 58 44 17 70
Aortic Arch Syndrome 57 12 20
Young Female Arteritis 57 20
Aortic Arch Syndromes 44 70
Takayasu's Arteritis 12 15
Aortic Arches Defect 73 20
Idiopathic Aortitis 12 70
Aortic Arch Defects 20 58
Pulseless Disease 57 20
Aortic Arch Arteritis 12
Takayasu's Disease 12
Takayasu Disease 20
Ta 20

Characteristics:

Orphanet epidemiological data:

58
takayasu arteritis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (United Kingdom),1-9/100000 (Japan),1-9/1000000 (Sweden),1-9/1000000 (United Kingdom); Age of onset: Adolescent,Adult; Age of death: adult;
aortic arch defects
Inheritance: Not applicable; Age of onset: Childhood;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
? autosomal recessive vs. autoimmune


HPO:

31
takayasu arteritis:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare circulatory system diseases
Rare cardiac malformations
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Developmental anomalies during embryogenesis


Summaries for Takayasu Arteritis

GARD : 20 Takayasu arteritis is a condition that causes inflammation of the main blood vessel that carries blood from the heart to the rest of the body ( aorta ) and its associated branched blood vessels. As a result of the inflammation, the blood vessel walls become thick and make it difficult for blood to flow. Over time, impaired blood flow causes damage to the heart and various other organs of the body. Although the cause remains unknown, Takayasu arteritis appears to be an autoimmune condition, in which cells that fight infection and disease are wrongly targeted against the body's own tissues.

MalaCards based summary : Takayasu Arteritis, also known as aortic arch syndrome, is related to vasculitis and aortitis. An important gene associated with Takayasu Arteritis is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Methotrexate and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and kidney, and related phenotypes are hyperhidrosis and fatigue

Disease Ontology : 12 A vasculitis that involves inflammation of the aorta that carries blood from the heart to the rest of the body.

Wikipedia : 73 Interrupted aortic arch is a very rare heart defect (affecting 3 per million live births) in which the... more...

More information from OMIM: 207600

Related Diseases for Takayasu Arteritis

Diseases related to Takayasu Arteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 864)
# Related Disease Score Top Affiliating Genes
1 vasculitis 32.2 VCAM1 TNF SELE PTX3 IL6 ICAM1
2 aortitis 31.5 TNF PTX3 IL6 CRP
3 coronary stenosis 31.4 IL6 ICAM1 CRP
4 ulcerative colitis 31.4 TNF IL6 ICAM1 HLA-DRB1 CRP
5 pyoderma 31.3 TNF MMP9 CRP
6 angina pectoris 31.2 IL6 ICAM1 CRP
7 aortic dissection 31.2 MMP9 MMP2 IL6 CRP
8 temporal arteritis 31.2 TNF PTX3 IL6 HLA-DRB1 CRP
9 intermediate coronary syndrome 31.1 VCAM1 IL6 CRP
10 sarcoidosis 1 31.1 TNF ICAM1 HLA-DRB1 HLA-A CRP
11 crohn's disease 31.1 TNF IL6 ICAM1 HLA-DRB1 FCGR3A CRP
12 pericarditis 31.0 TNF IL6 CRP
13 purpura 31.0 TNF IL6 CRP
14 pulmonary tuberculosis 31.0 TNF IL6 IL12B HLA-DRB1
15 antiphospholipid syndrome 31.0 VCAM1 TNF SELE CRP
16 uveitis 31.0 TNF IL6 ICAM1 HLA-B HLA-A
17 spondylitis 31.0 TNF IL6 HLA-B CRP
18 cardiogenic shock 31.0 TNF IL6
19 osteomyelitis 31.0 TNF IL6 CRP
20 scleritis 30.9 TNF SELE MMP9 CRP
21 acute myocardial infarction 30.9 SELE PTX3 MMP9 IL6 CRP
22 exanthem 30.9 TNF IL6 CRP
23 brucellosis 30.9 TNF IL6 CRP
24 pre-eclampsia 30.9 VCAM1 TNF SELE MMP9 IL6 ICAM1
25 spondyloarthropathy 1 30.9 TNF MMP3 IL6 HLA-B CRP
26 myocarditis 30.9 VCAM1 TNF IL6 ICAM1 HLA-B
27 thyroiditis 30.9 TNF IL6 HLA-DRB1 CRP
28 optic neuritis 30.8 TNF IL6 HLA-DRB1 HLA-A
29 familial mediterranean fever 30.8 TNF IL6 HLA-A CRP
30 subacute thyroiditis 30.8 TNF IL6 CRP
31 spondylarthropathy 30.8 TNF HLA-B
32 granulomatosis with polyangiitis 30.8 TNF SELE HLA-DPB1 CRP
33 rheumatic fever 30.8 TNF IL6 ICAM1 HLA-DRB1 FCGR2A
34 erythema nodosum 30.8 VCAM1 TNF SELE IL6 ICAM1 CRP
35 ischemic colitis 30.8 MMP9 MMP2 CRP
36 vascular disease 30.7 VCAM1 TNF SELE MMP9 MMP3 IL6
37 buerger disease 30.7 VCAM1 ICAM1 HLA-DRB1 HLA-DPB1 CRP
38 limb ischemia 30.7 TNF SELE MMP9 MMP2 IL6 ICAM1
39 placenta disease 30.7 TNF IL6 CRP
40 infective endocarditis 30.7 TNF IL6 FCGR2A CRP
41 carotid stenosis 30.7 VCAM1 TNF SELE MMP9 ICAM1 CRP
42 endocarditis 30.7 VCAM1 TNF IL6 FCGR2A CRP
43 polyarteritis nodosa 30.7 VCAM1 SELE IL6 ICAM1 HLA-DRB1 CRP
44 respiratory failure 30.6 TNF PTX3 IL6 ICAM1 CRP
45 lymphadenitis 30.6 TNF PTX3 ICAM1 CRP
46 juvenile rheumatoid arthritis 30.6 TNF MMP3 IL6 HLA-DRB1 HLA-DPB1 CRP
47 anterior scleritis 30.6 TNF CRP
48 end stage renal disease 30.6 TNF IL6 ICAM1 CRP
49 common variable immunodeficiency 30.6 TNF IL6 HLA-DRB1 HLA-B HLA-A
50 peripheral vascular disease 30.6 VCAM1 SELE IL6 CRP

Graphical network of the top 20 diseases related to Takayasu Arteritis:



Diseases related to Takayasu Arteritis

Symptoms & Phenotypes for Takayasu Arteritis

Human phenotypes related to Takayasu Arteritis:

58 31 (show all 48)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0000975
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
4 subcutaneous nodule 58 31 hallmark (90%) Very frequent (99-80%) HP:0001482
5 hypertensive crisis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100735
6 arterial stenosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100545
7 weight loss 58 31 hallmark (90%) Very frequent (99-80%) HP:0001824
8 vasculitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002633
9 abnormal aortic arch morphology 31 hallmark (90%) HP:0012303
10 muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0001324
11 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
12 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
13 abnormal aortic valve morphology 58 31 frequent (33%) Frequent (79-30%) HP:0001646
14 myocardial infarction 58 31 frequent (33%) Frequent (79-30%) HP:0001658
15 hypertrophic cardiomyopathy 58 31 frequent (33%) Frequent (79-30%) HP:0001639
16 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
17 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
18 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
19 migraine 58 31 frequent (33%) Frequent (79-30%) HP:0002076
20 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
21 inflammatory abnormality of the eye 58 31 frequent (33%) Frequent (79-30%) HP:0100533
22 pulmonary arterial hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0002092
23 gangrene 58 31 frequent (33%) Frequent (79-30%) HP:0100758
24 abnormal pattern of respiration 58 31 frequent (33%) Frequent (79-30%) HP:0002793
25 respiratory insufficiency 31 frequent (33%) HP:0002093
26 apnea 31 frequent (33%) HP:0002104
27 ascending tubular aorta aneurysm 31 frequent (33%) HP:0004970
28 seizure 31 frequent (33%) HP:0001250
29 neurological speech impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002167
30 reduced consciousness/confusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0004372
31 retinopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000488
32 arthralgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002829
33 hemoptysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002105
34 cerebral ischemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002637
35 gastrointestinal infarctions 58 31 occasional (7.5%) Occasional (29-5%) HP:0005244
36 amaurosis fugax 58 31 occasional (7.5%) Occasional (29-5%) HP:0100576
37 recurrent respiratory infections 31 occasional (7.5%) HP:0002205
38 feeding difficulties in infancy 31 occasional (7.5%) HP:0008872
39 asthma 31 occasional (7.5%) HP:0002099
40 abnormal endocardium morphology 31 occasional (7.5%) HP:0004306
41 seizures 58 Frequent (79-30%)
42 hypertension 58 Frequent (79-30%)
43 abnormal heart valve morphology 58 Very frequent (99-80%)
44 abnormality of the endocardium 58 Occasional (29-5%)
45 dilatation of the ascending aorta 58 Frequent (79-30%)
46 dilatation 58 Very frequent (99-80%)
47 increased inflammatory response 58 Frequent (79-30%)
48 arteritis 31 HP:0012089

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Vascular:
arteritis, major aortic branches

Limbs:
decreased pulses, upper limbs

Clinical features from OMIM®:

207600 (Updated 20-May-2021)

MGI Mouse Phenotypes related to Takayasu Arteritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 FCGR2A HLA-A ICAM1 IL12B IL6 LILRB3
2 immune system MP:0005387 9.47 CRP FCGR2A HLA-A ICAM1 IL12B IL6

Drugs & Therapeutics for Takayasu Arteritis

Drugs for Takayasu Arteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
2
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
3
Tofacitinib Approved, Investigational Phase 4 477600-75-2
4
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
5
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
6 Immunologic Factors Phase 4
7 Immunoglobulins Phase 4
8 Antibodies Phase 4
9 Anti-Inflammatory Agents Phase 4
10 Folic Acid Antagonists Phase 4
11 Vitamin B9 Phase 4
12 Folate Phase 4
13 Vitamin B Complex Phase 4
14 Protein Kinase Inhibitors Phase 4
15 Antimetabolites Phase 4
16 Immunoglobulins, Intravenous Phase 4
17
Mycophenolic acid Approved Phase 3 24280-93-1 446541
18
Azathioprine Approved Phase 3 446-86-6 2265
19
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
20
Upadacitinib Approved, Investigational Phase 3 1310726-60-3 58557659
21
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
22
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
23
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
24
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
25
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
26
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
27
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
28 Janus Kinase Inhibitors Phase 3
29 Methylprednisolone Acetate Phase 3
30 Immunosuppressive Agents Phase 2, Phase 3
31 glucocorticoids Phase 2, Phase 3
32 Hormones Phase 2, Phase 3
33 Hormone Antagonists Phase 2, Phase 3
34 Antineoplastic Agents, Hormonal Phase 2, Phase 3
35 Alkylating Agents Phase 2, Phase 3
36
Abatacept Approved Phase 2 332348-12-6 10237
37
Ethanol Approved Phase 2 64-17-5 702
38
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
39
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
40
Infliximab Approved Phase 2 170277-31-3
41 Narcotics Phase 2
42 Narcotic Antagonists Phase 2
43 Analgesics, Non-Narcotic Phase 2
44 Analgesics Phase 2
45 Interleukin-2 Phase 2
46 Antirheumatic Agents Phase 2
47 Gastrointestinal Agents Phase 2
48 Dermatologic Agents Phase 2
49
tannic acid Approved 1401-55-4
50
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Randomized Open-label Study in Mild and Moderate Patients With Takayasu Arteritis Between Methotrexate and Tofacitinib Based on the ECTA Cohort. Recruiting NCT04299971 Phase 4 Methotrexate Tablets;Tofacitinib tablet
2 A Pilot Study in the Treatment of Severe Patients With Takayasu Arteritis With Tocilizumab and Adalimumab, Based on ECTA Cohort Recruiting NCT04300686 Phase 4
3 Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis Unknown status NCT03096275 Phase 3 MMF;CYC;Glucocorticoids;MTX;AZA
4 Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study Completed NCT02101333 Phase 3 Tocilizumab
5 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu) Recruiting NCT04161898 Phase 3 Upadacitinib;Placebo for Upadacitinib;Prednisolone
6 Does Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment? Not yet recruiting NCT03550781 Phase 2, Phase 3 Prednisone, cyclophosphamide
7 Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis Unknown status NCT02457585 Phase 2 remicade (anti tumor necrosis factor inhibitor)
8 Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu's Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-Ig) in Large Vessel Vasculitis Completed NCT00556439 Phase 2 Abatacept;Placebo
9 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
10 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Active, not recruiting NCT01988506 Phase 2 Interleukin 2
11 Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis Not yet recruiting NCT04564001 Phase 2 Infliximab;Tocilizumab
12 Exercise in Juvenile Takayasu Disease: a Randomized Controlled Trial Unknown status NCT03494062
13 Registration Study of Takayasu's Arteritis in China Unknown status NCT03199183
14 Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis Unknown status NCT01501019
15 Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded Trial Unknown status NCT02981979 Leflunomide 10mg Tab;Prednisone Acetate;Placebos
16 A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments Unknown status NCT03192878 Infliximab
17 ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
18 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
19 Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria Unknown status NCT03133949
20 Contrast Enhanced Ultrasound for Assessment of Carotid Artery Neovascularization as a Marker of Disease Activity in Takayasu's Arteritis and Giant Cell Arteritis Completed NCT01795456
21 VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-vessel Vasculitis (Takayasu's Arteritis):Development as Clinical Trial Outcome Measures Completed NCT00744952
22 Pulmonary Artery Involvement in Takayasu's Arteritis: a Retrospective Study in China Completed NCT03189602
23 Impact and Utility of Positron Emission Tomography (PET) for the Assessment of Inflammatory Activity Arteritis Versus Clinical Score and Laboratory Values in Takayasu Arteritis: a Cohort Study Completed NCT01532167
24 The Long-term Success of Cardiovascular Surgery in Takayasu Arteritis. 30 Years of Experience in Mexico, Beyond Forefront Techniques Completed NCT03654222
25 Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry Completed NCT02476292
26 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
27 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
28 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Completed NCT03941184
29 VCRC Validation of Patient-Reported Diagnostic Data Completed NCT02190942
30 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
31 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
32 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
33 The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases Completed NCT02925351 Early Phase 1
34 Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging Recruiting NCT03956394
35 Observational Multicenter Study of Refractory and/or Relapsing Takayasu Arteritis START: Study of Refractory and/or Relapsing TAkayasu aRTeritis Recruiting NCT03543527
36 A Registry Study on Biomarkers of Takayasu's Arteritis Recruiting NCT03372980
37 Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis Recruiting NCT02257866
38 The Cohort Study of East Chinese Takayasu's Arteritis (ECTA-cohort Study) Recruiting NCT03893136 Leflunomide
39 Aerobic Capacity and Strength Exercise in Takayasu's Arteritis: Impact on Clinical, Laboratory and Vascular Parameters Recruiting NCT03750929
40 China Takayasu Arteritis Registry (CTA Registry) Recruiting NCT02964364
41 The PET Imaging of Giant Cell and Takayasu Arteritis Study Recruiting NCT04071691
42 The Vasculitis Pregnancy Registry (V-PREG) Recruiting NCT02593565
43 Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes Recruiting NCT02006134
44 VCRC Tissue Biorepository Collection Protocol Recruiting NCT02967068
45 VCRC Longitudinal Protocol for Takayasu's Arteritis Active, not recruiting NCT00315471
46 VCRC Genetic Repository One-Time DNA Protocol Active, not recruiting NCT01241305
47 The Effects and Safety of Drug-coated Balloon in the Treatment of Hypertension Caused by Takayasu Arteritis Associated Renal Artery Stenosis: a Single Centre, Random, Double Blind Trial Not yet recruiting NCT04137614

Search NIH Clinical Center for Takayasu Arteritis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Alprostadil

Cochrane evidence based reviews: takayasu arteritis

Genetic Tests for Takayasu Arteritis

Anatomical Context for Takayasu Arteritis

MalaCards organs/tissues related to Takayasu Arteritis:

40
Heart, Bone, Kidney, Lung, Eye, Endothelial, Skin

Publications for Takayasu Arteritis

Articles related to Takayasu Arteritis:

(show top 50) (show all 2207)
# Title Authors PMID Year
1
Identification of multiple genetic susceptibility loci in Takayasu arteritis. 57 61
23830517 2013
2
Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. 61 57
23830516 2013
3
Matrix metalloproteinases as novel disease markers in Takayasu arteritis. 57 61
12952836 2003
4
DNA typing of HLA-B gene in Takayasu's arteritis. 61 57
7903491 1993
5
Takayasu's disease in twin sisters. 57
6145807 1984
6
HLA-DR MT and MB antigens in Takayasu disease. 57
6134351 1983
7
Association between Takayasu's arteritis and a B-cell alloantigen in North Americans. 57
6977091 1982
8
Association between Takayasu disease and HLA-DHO. 57
91228 1979
9
HL-A antigens in Takayasu's disease. 57
36742 1979
10
HLA-Bw52 in Takayasu disease. 57
31708 1978
11
Takayasu's disease in twin sisters. Possible genetic factors. 57
25719 1978
12
TAKAYASU'S ARTERITIS. REPORT OF FIVE CASES WITH IMMUNOLOGIC STUDIES. 57
14176969 1964
13
Serum C1q concentration is associated with disease activity in Chinese Takayasu arteritis patients: A case-control study. 61
33778164 2021
14
Evaluation of tocilizumab for intractable Takayasu arteritis and 18F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment. 61
33451862 2021
15
When Both the Right Ventricle and the Pulmonary Artery "Light Up": A Case of Takayasu Arteritis. 61
33199182 2021
16
Therapeutic strategy for the patients with Takayasu arteritis and heart failure. 61
33388401 2021
17
Late Diagnosis of Takayasu Arteritis With Unusual Development of Collaterals in Brain and Upper Extremities. 61
32888631 2021
18
Multiple occlusions in extracranial arteries in patients with aortic arch syndrome: is minimally invasive treatment still possible? Technical aspects of the treatment based on our own experience and a review of the literature. 61
33786133 2021
19
Evaluating renal arterial wall by non-enhanced 2D and 3D free-breathing black-blood techniques: Initial experience. 61
33677024 2021
20
Large vessel vasculitis: imaging standards of 18F-FDG PET/CT. 61
33106969 2021
21
A Large Mediastinal Mass in a Young Woman: A Case of Giant Coronary Artery Aneurysm. 61
33741325 2021
22
CT findings in aggressive Takayasu arteritis. 61
33787451 2021
23
The feasible maintenance dose of corticosteroid in Takayasu arteritis in the era of biologic therapy. 61
33729078 2021
24
Surgical treatment for brachiocephalic artery aneurysm with Takayasu arteritis using isolated cerebral perfusion: a case study. 61
33743755 2021
25
Abdominal Pyoderma Gangrenosum, Harbinger of Takayasu Arteritis in an African American Patient. 61
30044262 2021
26
Poor maternal and foetal outcomes in women with systemic sclerosis: an interview-based study at a tertiary centre. 61
33682026 2021
27
Risk factors for cerebral infarction in Takayasu arteritis: a single-centre case-controlled study. 61
33774663 2021
28
Poor physical activity levels and cardiorespiratory fitness among patients with childhood-onset takayasu arteritis in remission: a cross-sectional, multicenter study. 61
33752674 2021
29
Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Based Retrospective Cohort Study From the United Kingdom. 61
32969145 2021
30
Endovascular Treatment of Acute Type B Aortic Dissection in a Patient with Takayasu Arteritis. 61
33727068 2021
31
Endovascular management of symptomatic stenosis of supra-aortic arteries in patients with Takayasu arteritis. 61
33350653 2021
32
Complex redo cervical and vertebral artery reconstruction for Takayasu arteritis. 61
33665537 2021
33
Etiology spectrum and clinical characteristics of renal artery stenosis in a Chinese cohort. 61
33747059 2021
34
Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides. 61
33569633 2021
35
Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature. 61
33095281 2021
36
Submitral aneurysm of varied aetiologies: a case series. 61
33738423 2021
37
Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. 61
33512787 2021
38
Clinical features of large vessel vasculitis (LVV): Elderly-onset versus young-onset. 61
33480825 2021
39
Aortitis: recent advances, current concepts and future possibilities. 61
33593995 2021
40
Granulocyte colony stimulating factor-associated aortitis evaluated via multiple imaging modalities including vascular echography: a case report. 61
33598604 2021
41
Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis. 61
33627173 2021
42
18F-FDG PET/CT plays a unique role in the management of Takayasu arteritis patients with atypical manifestations. 61
32562071 2021
43
Comment on: Different treatment options for Takayasu arteritis patients with moderate-to-severe aortic regurgitation: long-term outcomes. 61
33617627 2021
44
Successful Endovascular Repair of an Aortobronchial Fistula due to Takayasu Arteritis. 61
32949744 2021
45
Childhood-onset versus adult-onset Takayasu arteritis: A study of 141 patients from Turkey. 61
33383295 2021
46
Prevalence of Takayasu Arteritis: A Population-based Study. 61
33589549 2021
47
Pulmonary findings on high-resolution computed tomography in Takayasu arteritis. 61
33590834 2021
48
The Impact of Integrated Noninvasive Imaging in the Management of Takayasu Arteritis. 61
32682724 2021
49
Cardiac valvular involvement of Takayasu arteritis. 61
32666179 2021
50
Pulmonary artery involvement in Takayasu arteritis: a retrospective study in Chinese population. 61
32643055 2021

Variations for Takayasu Arteritis

Expression for Takayasu Arteritis

Search GEO for disease gene expression data for Takayasu Arteritis.

Pathways for Takayasu Arteritis

Pathways related to Takayasu Arteritis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 VCAM1 TNF PTX3 MMP9 MMP3 MMP2
2
Show member pathways
13.47 VCAM1 LILRB3 ICAM1 HLA-DRB1 HLA-DPB1 HLA-B
3
Show member pathways
13.34 VCAM1 TNF MMP9 MMP3 MMP2 IL6
4
Show member pathways
13.24 VCAM1 TNF SELE MMP9 MMP3 IL6
5
Show member pathways
12.94 TNF IL6 IL12B ICAM1 HLA-DRB1 HLA-DPB1
6
Show member pathways
12.91 TNF IL6 IL12B ICAM1 HLA-DRB1 HLA-DPB1
7 12.87 TNF IL6 IL12B HLA-DRB1 HLA-DPB1 HLA-B
8
Show member pathways
12.76 VCAM1 MMP9 MMP3 MMP2 ICAM1
9
Show member pathways
12.71 VCAM1 TNF LILRB3 ICAM1 FCGR3A FCGR2A
10
Show member pathways
12.62 TNF IL6 IL12B HLA-DRB1 HLA-DPB1
11
Show member pathways
12.61 VCAM1 ICAM1 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
12
Show member pathways
12.55 TNF ICAM1 HLA-B HLA-A FCGR3A
13 12.41 TNF IL6 ICAM1 HLA-DRB1 HLA-DPB1 HLA-B
14
Show member pathways
12.36 TNF IL12B HLA-DRB1 HLA-DPB1 FCGR3A FCGR2A
15
Show member pathways
12.35 TNF IL6 ICAM1 CRP
16
Show member pathways
12.34 TNF MMP9 MMP3 IL6
17 12.32 TNF MMP9 MMP2 IL12B
18
Show member pathways
12.29 TNF IL6 IL12B HLA-B HLA-A
19 12.28 TNF IL6 IL12B HLA-DRB1 HLA-DPB1 FCGR3A
20 12.24 HLA-DRB1 HLA-DPB1 HLA-B HLA-A FCGR3A FCGR2A
21 12.21 TNF MMP9 MMP2 IL6
22 12.2 VCAM1 TNF SELE MMP9 MMP2 ICAM1
23 12.17 VCAM1 LILRB3 ICAM1 HLA-B HLA-A FCGR3A
24 12.15 VCAM1 SELE ICAM1 HLA-DRB1 HLA-DPB1 HLA-B
25 12.11 VCAM1 MMP9 MMP3 MMP2 ICAM1
26 12.1 TNF MMP9 LILRB3 IL6 ICAM1 FCGR2A
27 12 ICAM1 HLA-DRB1 HLA-DPB1 FCGR3A FCGR2A
28 11.99 VCAM1 TNF SELE MMP2 IL6 ICAM1
29
Show member pathways
11.96 TNF MMP9 MMP3 MMP2
30 11.96 TNF IL6 HLA-DRB1 HLA-DPB1
31 11.94 TNF MMP3 IL6 ICAM1 HLA-DRB1 HLA-DPB1
32 11.85 VCAM1 TNF SELE MMP9 MMP3 IL6
33 11.81 SELE IL6 ICAM1
34
Show member pathways
11.77 TNF IL6 IL12B
35 11.77 TNF IL6 IL12B
36 11.7 VCAM1 TNF IL6 ICAM1 FCGR3A FCGR2A
37 11.69 MMP9 MMP2 IL6
38 11.66 MMP9 MMP3 MMP2
39 11.65 VCAM1 TNF SELE IL6 ICAM1
40 11.64 TNF PTX3 MMP9 MMP2 IL6 IL12B
41 11.63 TNF IL6 IL12B
42 11.62 TNF IL6 IL12B ICAM1
43 11.62 TNF MMP9 MMP2 IL6 ICAM1
44 11.61 SELE MMP2 IL6
45 11.61 VCAM1 TNF MMP9 MMP3 MMP2 IL6
46 11.58 TNF MMP2 IL6
47 11.51 VCAM1 SELE ICAM1
48 11.44 SELE MMP9 MMP3
49 11.38 MMP9 MMP2 IL6
50 11.37 TNF IL6 IL12B HLA-DRB1

GO Terms for Takayasu Arteritis

Cellular components related to Takayasu Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.96 VCAM1 TNF SELE LILRB3 ICAM1 HLA-DRB1
2 external side of plasma membrane GO:0009897 9.85 VCAM1 TNF IL12B ICAM1 HLA-DRB1 FCGR3A
3 cell surface GO:0009986 9.76 VCAM1 TNF IL12B ICAM1 HLA-DRB1 HLA-DPB1
4 ER to Golgi transport vesicle membrane GO:0012507 9.62 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
5 MHC class I protein complex GO:0042612 9.4 HLA-B HLA-A
6 extracellular space GO:0005615 9.4 VCAM1 TNF SELE PTX3 MMP9 MMP3
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-DRB1 HLA-DPB1 HLA-B HLA-A

Biological processes related to Takayasu Arteritis according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.15 LILRB3 HLA-DRB1 HLA-DPB1 HLA-B HLA-A FCGR2A
2 neutrophil degranulation GO:0043312 10.08 PTX3 MMP9 LILRB3 HLA-B FCGR2A
3 adaptive immune response GO:0002250 10.07 LILRB3 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
4 inflammatory response GO:0006954 10.03 TNF SELE PTX3 IL6 CRP
5 immune response GO:0006955 9.98 TNF IL6 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
6 leukocyte migration GO:0050900 9.95 TNF SELE MMP9 ICAM1
7 cellular response to lipopolysaccharide GO:0071222 9.92 TNF IL6 IL12B ICAM1
8 defense response to Gram-positive bacterium GO:0050830 9.87 TNF IL6 HLA-A CRP
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF IL6 IL12B
10 extracellular matrix disassembly GO:0022617 9.83 MMP9 MMP3 MMP2
11 positive regulation of interferon-gamma production GO:0032729 9.83 TNF IL12B HLA-DPB1 HLA-A
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 TNF MMP2 IL6
13 positive regulation of T cell proliferation GO:0042102 9.81 VCAM1 IL6 IL12B HLA-DPB1
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.8 TNF MMP9 MMP2
15 regulation of immune response GO:0050776 9.8 VCAM1 ICAM1 HLA-B HLA-A FCGR3A FCGR2A
16 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.79 VCAM1 SELE ICAM1
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 TNF PTX3 ICAM1
18 collagen catabolic process GO:0030574 9.77 MMP9 MMP3 MMP2
19 leukocyte cell-cell adhesion GO:0007159 9.75 VCAM1 SELE ICAM1
20 leukocyte tethering or rolling GO:0050901 9.73 VCAM1 TNF SELE
21 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.72 TNF IL6 ICAM1
22 response to amyloid-beta GO:1904645 9.71 MMP9 MMP3 MMP2
23 extracellular matrix organization GO:0030198 9.7 VCAM1 TNF PTX3 MMP9 MMP3 MMP2
24 T-helper 1 type immune response GO:0042088 9.68 IL12B HLA-DRB1
25 positive regulation of memory T cell differentiation GO:0043382 9.67 IL12B HLA-DRB1
26 detection of bacterium GO:0016045 9.67 HLA-DRB1 HLA-B HLA-A
27 antigen processing and presentation GO:0019882 9.67 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
28 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.66 HLA-B HLA-A
29 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.65 HLA-B HLA-A
30 regulation of neuroinflammatory response GO:0150077 9.65 MMP9 MMP3 IL6
31 vascular endothelial growth factor production GO:0010573 9.64 TNF IL6
32 opsonization GO:0008228 9.64 PTX3 CRP
33 protection from natural killer cell mediated cytotoxicity GO:0042270 9.63 HLA-B HLA-A
34 cellular response to UV-A GO:0071492 9.63 MMP9 MMP3 MMP2
35 membrane to membrane docking GO:0022614 9.61 VCAM1 ICAM1
36 negative regulation by host of viral process GO:0044793 9.58 PTX3 CRP
37 negative regulation of lipid storage GO:0010888 9.58 TNF IL6 CRP
38 positive regulation of T cell mediated cytotoxicity GO:0001916 9.56 IL12B HLA-DRB1 HLA-B HLA-A
39 cytokine-mediated signaling pathway GO:0019221 9.56 VCAM1 TNF MMP9 MMP3 MMP2 IL6
40 interferon-gamma-mediated signaling pathway GO:0060333 9.1 VCAM1 ICAM1 HLA-DRB1 HLA-DPB1 HLA-B HLA-A

Molecular functions related to Takayasu Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell receptor binding GO:0042608 9.37 HLA-DRB1 HLA-A
2 transmembrane signaling receptor activity GO:0004888 9.35 SELE LILRB3 ICAM1 FCGR3A FCGR2A
3 IgG binding GO:0019864 9.32 FCGR3A FCGR2A
4 complement component C1q binding GO:0001849 9.26 PTX3 CRP
5 TAP binding GO:0046977 9.16 HLA-B HLA-A
6 peptide antigen binding GO:0042605 8.92 HLA-DRB1 HLA-DPB1 HLA-B HLA-A

Sources for Takayasu Arteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....